STOCK TITAN
  1. Home
  2. News
  3. EDIT

Editas Medicine Inc - EDIT STOCK NEWS

Welcome to our dedicated news page for Editas Medicine (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Editas Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Editas Medicine's position in the market.

News
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Rhea-AI Summary
Editas Medicine, a clinical-stage gene editing company, is set to present pre-clinical data at the ASGCT Annual Meeting. The company will showcase advancements in in vivo gene editing technologies, including the delivery of CRISPR/Cas12a for treating Myocilin-Associated Glaucoma. Editas aims to develop transformative in vivo gene editing medicines, with a focus on optimizing guide RNA modifications and identifying potent recombinases. The presentations will demonstrate the potential for high-potency gene editing in various cell types and the development of novel gene editing technologies for targeted gene insertion. Overall, Editas is making progress towards confirming in vivo proof of concept by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
News
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
Rhea-AI Summary
Editas Medicine, Inc. (EDIT) reports financial results and business updates for Q4 and full year 2023. The company made progress in its reni-cel program for Sickle Cell Disease and Beta Thalassemia, with promising data shared and enrollment ongoing. Editas also entered a license agreement with Vertex Pharmaceuticals for Cas9 gene editing technology. Financially, the company has a strong position with cash, cash equivalents, and marketable securities expected to fund operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.94%
Tags
earnings
-
News
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
Rhea-AI Summary
Editas Medicine, Inc. (Nasdaq: EDIT) will host a conference call and webcast on February 28, 2024, to discuss Q4 and full-year 2023 results and provide a corporate update. Management will also participate in upcoming investor conferences. Investors can access webcasts on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
conferences earnings
News
Editas Medicine to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Editas Medicine, Inc. (Nasdaq: EDIT) will participate in upcoming investor conferences to discuss the Company and its programs, including reni-cel. The conferences include the Guggenheim 6th Annual Biotechnology Conference and the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The live webcasts of the presentations will be available on the Company’s website, with archived replays for approximately 30 days following each event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
conferences
-
News
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
Rhea-AI Summary
Editas Medicine, Inc. (Nasdaq: EDIT) announces 2024 strategic priorities and anticipated milestones, including clinical data updates, clinical trial initiation, and business development activities. Dr. Gilmore O’Neill, President and CEO, to present at the 42nd Annual J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.52%
Tags
none
-
News
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Editas Medicine, Inc. (Nasdaq: EDIT) announced that President and CEO Gilmore O’Neill will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. A live webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
conferences
News
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
Rhea-AI Summary
Editas Medicine, Inc. (Nasdaq: EDIT) has entered into a non-exclusive license agreement with Vertex Pharmaceuticals for its Cas9 gene editing technology targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, including CASGEVY™ (exagamglogene autotemcel). This agreement extends Editas Medicine’s cash runway into 2026. The company holds exclusive rights to certain CRISPR patent estates for making human medicines, including a Cas9 patent estate owned and co-owned by Harvard University, Broad Institute, the Massachusetts Institute of Technology, and The Rockefeller University.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
none
-
News
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
Rhea-AI Summary
Editas Medicine, Inc. (Nasdaq: EDIT) announced new safety and efficacy data in 17 patients treated with EDIT-301, now known as renizgamglogene autogedtemcel (reni-cel), in the RUBY trial for severe sickle cell disease (SCD) and in the EdiTHAL trial for transfusion-dependent beta thalassemia (TDT). All patients treated in the RUBY trial are free of vaso-occlusive events post-EDIT-301 infusion, and all RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40%. The company-sponsored webinar will present the RUBY and EdiTHAL trial data, and the data will also be presented in a poster presentation at the American Society of Hematology (ASH) Annual Meeting. Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant by all patients in the two trials (n=17).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
News
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
Rhea-AI Summary
Editas Medicine, Inc. reported financial results for Q3 2023 and provided business updates. They will share clinical data updates from the RUBY trial for SCD and the EdiTHAL trial for TDT in December. They granted Vor Bio a non-exclusive license for Cas9 patents. They appointed Caren Deardorf as the Chief Commercial and Strategy Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.21%
Tags
earnings
News
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
Rhea-AI Summary
Editas Medicine, Inc. will host a webinar on December 11, 2023, to discuss the clinical data from the RUBY and EdiTHAL trials of EDIT-301. The scientific abstract detailing safety and efficacy data has been accepted for a poster presentation at the ASH Annual Meeting. Key data on patient outcomes, including total hemoglobin, fetal hemoglobin, vaso-occlusive events, neutrophil and platelet engraftment, will be shared. The company believes that EDIT-301 has the potential to be a one-time, durable medicine for patients with severe sickle cell disease and transfusion-dependent beta thalassemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
conferences clinical trial
Stock EDIT logo
Editas Medicine Inc

Nasdaq:EDIT

EDIT Rankings

#3052 Ranked by Market Cap
#4674 Ranked by Stock Gains
N/A Ranked by Dividends

EDIT Stock Data

508.06M
75.99M
0.91%
80.47%
20%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About EDIT

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.